# Reid Huber

> Reid Huber is a Series A investor at Third Rock Ventures backing Biotechnology and Medical. See 12 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Third Rock Ventures](https://shizune.co/investors/profile/third-rock-ventures)
- Location: Boston, United States
- Total investments: 12
- Last investment: Apr 2026
- Lead investor: 67%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/reid-huber-2374277
- Website: https://x.com/ReidHuber
- Facebook: https://www.facebook.com/reid.huber

Reid Huber is a Series A investor at Third Rock Ventures in Boston focused on Biotechnology and Medical. Reid Huber is based out of Boston, Massachusetts and is the Partner of Third Rock Ventures. Reid previously worked at Bellicum Pharmaceuticals as a Director. Reid Huber attended the Washington University School of Medicine in St. Louis.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 5 | 42% |
| Medical | 3 | 25% |
| Life Science | 3 | 25% |
| Therapeutics | 3 | 25% |
| Health Care | 2 | 17% |

6 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 7 | 58% |
| Series B | 3 | 25% |
| Series C | 2 | 17% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Terremoto Biosciences | Terremoto Biosciences is a biotechnology company leveraging the power of lysine-based covalency to develop optimized medicines. | $108M | Series C | Apr 15, 2026 |  |
| Syremis Therapeutics | Syremis Therapeutics is developing novel medicines to make a profound impact on the treatment of mental health disorders. | $165M | Series A | Dec 18, 2025 |  |
| Merida Biosciences | Merida Biosciences is a new biotech company focused on developing precision treatments, particularly for autoimmune diseases. The company utilize a protein engineering platform to create unique Fc therapeutics, aiming to selectively bind to specific antibodies. | $121M | Series A | Apr 08, 2025 |  |
| Asher Bio | Asher Bio is an information technology company that specializes in the fields of CFO Office transformation, profitability, and cost management. It focuses on building and developing better immunotherapy for cancer. The company was founded in 2019 and headquartered in San Francisco, California. | $55M | Series C | Apr 16, 2024 |  |
| Synnovation Therapeutics | Synnovation Therapeutics is a precision oncology company focused on small molecule therapies optimized to target key driver mechanisms in cancers. It is dedicated to the discovery and development of therapeutics that can improve the lives of people with cancer. Leveraging its deep expertise in medicinal chemistry, cancer biology, andpatient-focused precision medicine, it builds a diverse pipeline of novel small-molecule targeted therapies. It aims to efficiently advance these agents into clinical trials with the goal of transforming cancer patient care. | $102M | Series A | Dec 14, 2023 |  |
| Terremoto Biosciences | Terremoto Biosciences is a biotechnology company leveraging the power of lysine-based covalency to develop optimized medicines. | $175M | Series B | Nov 02, 2023 |  |
| Rapport Therapeutics | Rapport Therapeutics operates as a clinical-stage biotechnology company, that discovers and develops precision medicines for neurological disorders. Rapport Therapeutics describes relationships that are defined by understanding, communication, teamwork, and trust. | $100M | Series A | Mar 07, 2023 |  |
| CARGO Therapeutics | CARGO Therapeutics develops CAR T-cell therapy to overcome cancer treatment resistance and address access barriers so that more patients can benefit from potentially curative therapies. The company is on a mission to outwit cancer by developing best-in-class chimeric antigen receptor (CAR) T-cell therapies. Despite commercially available autologousCARs advancements, these treatments are curative for less than half of all cancer patients. Furthermore, far too many patients are unable to access these potentially curative therapies due to other obstacles such as manufacturing, supply constraints, long turnaround times, and reimbursement barriers. CARGO's team is intensely focused on pursuing novel solutions to improve cancer treatment outcomes and experiences. | $200M | Series A | Mar 01, 2023 |  |
| Terremoto Biosciences | Terremoto Biosciences is a biotechnology company leveraging the power of lysine-based covalency to develop optimized medicines. | $75M | Series A | May 25, 2022 |  |
| Merida Biosciences | Merida Biosciences is a new biotech company focused on developing precision treatments, particularly for autoimmune diseases. The company utilize a protein engineering platform to create unique Fc therapeutics, aiming to selectively bind to specific antibodies. |  | Seed | Jan 01, 2022 |  |

10 of 12 investments shown.

## Co-investors
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund, 6 deals together
- [Boxer Capital](https://shizune.co/investors/profile/boxer-capital) — VC Fund, 3 deals together
- [Janus Henderson Investors](https://shizune.co/investors/profile/janus-henderson-investors) — VC Fund, 3 deals together
- [RA Capital Management](https://shizune.co/investors/profile/ra-capital-management) — VC Fund, 3 deals together
- [Wellington Management](https://shizune.co/investors/profile/wellington-management) — VC Fund, 3 deals together
- [Bain Capital Life Sciences](https://shizune.co/investors/profile/bain-capital-life-sciences) — VC Fund, 2 deals together

## About Third Rock Ventures

VC Fund · Boston, United States

Third Rock Ventures invests in transformational life science companies that show high growth potential and are well-positioned to make a difference in the marketplace. Third Rock Ventures believes in the companies we start and makes significant initial investments, which are frequently supplemented by strategic collaborations, to help our firmsprogress in life-changing medicines, technologies, and diagnostics.

5 contacts available at Third Rock Ventures.

| Name | Title | Profile |
| --- | --- | --- |
| Cary Pfeffer | Partner | https://shizune.co/investors/profile/cary-pfeffer |
| Jeff Tong | Partner | https://shizune.co/investors/profile/jeff-tong |
| Jigar Raythatha | Partner | https://shizune.co/investors/profile/jigar-raythatha |
| Mark Levin | Partner | https://shizune.co/investors/profile/mark-levin |
| Reid Huber | Partner | https://shizune.co/investors/profile/reid-huber |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Reid Huber invest in?

Reid Huber invests primarily in Biotechnology, Medical and Life Science startups, most often at Series A and Series B stage. Most of the 12 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Reid Huber last invest?

The most recent investment recorded for Reid Huber closed in Apr 2026. Shizune tracks 12 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co